← ANALYST RATINGS · TIPRANKS
AbbVie (ABBV): analyst forecast and price target
Analyst consensus
Strong Buy20 Buy4 Hold0 Sell
Ratings of 24 analysts in the last 3 months12-month forecast
Based on 24 price targets given in the last 3 months, the average target is $287, the highest $320, the lowest $225. The average is +0.4% from the last price of $285.
Analyst ratings 28
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $305 → $307+0.7% | Hold | +7.6% | Downgrade | 17.10.26on TipRanks 14:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $302 → $304+0.7% | Hold | +6.5% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $305 → $307+0.7% | Hold | +7.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $293 → $295+0.7% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $315 → $317+0.6% | Buy | +11.1% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $302 → $304+0.7% | Hold | +6.5% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $300 | Buy | +5.1% | Reiterated | 15.10.26on TipRanks 07:30 | +0.3%next day +1.8% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $320 | Buy | +12.1% | Reiterated | 14.10.26on TipRanks 09:25 | +4.4%next day +0.3% | ↗ |
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $280 | Buy | −1.9% | Reiterated | 13.10.26on TipRanks 07:09 | −2.4%next day +4.4% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $300 | Buy | +5.1% | Reiterated | 12.10.26on TipRanks 09:30 | +1.7%next day −2.4% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $260 | Hold | −8.9% | Reiterated | 12.10.26on TipRanks 08:01 | +1.7%next day −2.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $260 → $275+5.8% | Hold | −3.7% | Assigned | 09.10.26on TipRanks 08:40 | +0.9%next day +1.7% · 5 days +5.8% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $289 → $305+5.5% | Buy | +6.9% | Reiterated | 09.10.26on TipRanks 06:50 | +0.9%next day +1.7% · 5 days +5.8% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $288 | Buy | +0.9% | Reiterated | 08.10.26on TipRanks Oct 9 08:50 | +0.8%next day +0.9% · 5 days +4.9% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $285 → $300+5.3% | Buy | +5.1% | Assigned | 08.10.26on TipRanks 07:25 | +0.8%next day +0.9% · 5 days +4.9% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $285 → $290+1.8% | Buy | +1.6% | Assigned | 08.10.26on TipRanks 07:10 | +0.8%next day +0.9% · 5 days +4.9% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $303 | Buy | +6.2% | Reiterated | 08.10.26on TipRanks 07:07 | +0.8%next day +0.9% · 5 days +4.9% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | — | Buy | — | Reiterated | 07.10.26on TipRanks Oct 8 06:00 | +2.0%next day +0.8% · 5 days +5.4% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $310 | Buy | +8.6% | Assigned | 07.10.26on TipRanks 08:15 | +2.0%next day +0.8% · 5 days +5.4% | ↗ |
| Tim Anderson★★★★★★★★★★#1747 · hits 62% · avg +11.2% | Bank of America Securities | $289 | Buy | +1.3% | Reiterated | 29.09.26on TipRanks 06:30 | −0.9%next day −0.4% · 5 days −0.7% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $290 | Buy | +1.6% | Reiterated | 28.09.26on TipRanks Sep 29 07:35 | +1.5%next day −0.9% · 5 days −1.4% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 28.09.26on TipRanks 11:06 | +1.5%next day −0.9% · 5 days −1.4% | ↗ |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $280 | Buy | −1.9% | Reiterated | 28.09.26on TipRanks 04:30 | +1.5%next day −0.9% · 5 days −1.4% | ↗ |
| Luisa Hector★★★★★★★★★★#3558 · hits 58% · avg +4.9% | Berenberg Bank | $275 | Buy | −3.7% | Reiterated | 10.09.26on TipRanks Sep 11 09:50 | +2.2%next day 0.0% · 5 days +2.9% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $300 → $315+5.0% | Buy | +10.4% | Reiterated | 10.09.26on TipRanks 06:30 | +2.2%next day 0.0% · 5 days +2.9% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | $300 | Buy | +5.1% | Upgrade | 13.08.26on TipRanks 11:50 | +0.1%next day −0.3% · 5 days +6.4% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $300 | Buy | +5.1% | Reiterated | 11.08.26on TipRanks Aug 12 05:15 | +1.2%next day −0.8% · 5 days +3.9% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $246 → $260+5.7% | Buy | −8.9% | Assigned | 10.08.26on TipRanks 08:20 | +0.8%next day +1.2% · 5 days +1.0% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Buy | — | Upgrade | 05.08.26on TipRanks 10:14 | +1.2%next day −0.8% · 5 days +0.7% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $225 | Hold | −21.2% | Reiterated | 22.07.26on TipRanks Jul 24 05:15 | −1.0%next day +2.7% · 5 days +6.4% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $244 | Hold | −14.5% | Reiterated | 21.07.26on TipRanks Jul 24 05:15 | +0.2%next day −1.0% · 5 days +3.8% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $250 | Buy | −12.4% | Reiterated | 13.05.26on TipRanks May 18 13:05 | −0.3%next day +0.3% · 5 days +2.0% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $230 | Hold | −19.4% | Reiterated | 25.02.26on TipRanks 08:45 | −1.5%next day −0.4% · 5 days +5.2% | ↗ |
| Elmar Kraus★★★★★★★★★★#2504 · hits 70% · avg +9.8% | DZ BANK AG | $237 | Hold | −17.0% | Downgrade | 04.11.25on TipRanks 05:15 | +3.0%next day +0.1% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering AbbVie
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $282 at a price of $262 (+7.7%); now: $287 at $285 (+0.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 45 | 53 | 48 | 51 | 50 | 44 |
| Hold | 8 | 11 | 10 | 9 | 6 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $3.74 (from $3.61 to $3.77). Last quarter: $3.65.
Sales
Next quarter’s sales estimate — $17.4B (from $17.2B to $17.6B). Last quarter: $17.0B.
Best top-analyst consensus in the sector · Healthcare
About AbbVie
- CEO: Robert A. Michael
- Employees: 57,000
- 1 North Waukegan Road, North Chicago, IL, 60064-6400, US
- www.abbvie.com
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calc
Data from the stock’s TipRanks forecast page, read 19 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗